戻る Agenda
RWE Supporting HTA/Payers Determine the Value of Highly Innovative Medicines
Session Chair(s)
Sophie Schmitz
Managing Partner
P4A Partners for Access, Netherlands
RWE Supporting HTA/Payers Determine the Value of Highly Innovative Medicines
Learning Objective : - Share latest insights from the RWE4Decisions payer-led learning network - Discuss how transparency of RWE generation and evaluation can be improved - Explore how partnerships within and across stakeholders can be encouraged to align RWD requirements
Speaker(s)
Life Cycle of Real World Evidence Generation to Help HTA/Payers Determine the Value of Highly Innovative Medicines
Sophie Schmitz
P4A Partners for Access, Netherlands
Managing Partner
Perspective Matters When Assessing the Value of Precision Medicine
Charles Alessi
FT3, Belgium
Independent Expert
Data Design Principles for Value Exchange in Complex, Multi-Stakeholder Environments
Philippe Page, DrSc
The Human Colossus Foundation, Switzerland
Head of Research Council, Trustee
Challenges of Developing Robust RWE Studies for 27 Member States
Alexander Natz, JD
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Secretary General